logo
ScreenersREIT EarningsREIT SectorsIndustriesMarketplace
Logo

NextCure, Inc.

NXTC

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I forā€¦ read more

Healthcare

Biotechnology

6 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$13.37

Price

-1.62%

-$0.22

$13.59

Previous Close

$13.80

Open

Premium

52w Discount
Market Cap

$35.828m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$58.011m

-4.2%

1y CAGR

+7.7%

3y CAGR

+3.9%

5y CAGR
EPS

-$24.18

-1.3%

1y CAGR

+8.9%

3y CAGR

+4.9%

5y CAGR
Book Value

$23.646m

$39.613m

Assets

$15.967m

Liabilities

$4.411m

Debt
Debt to Assets

11.1%

-0.1x

Debt to EBITDA
Free Cash Flow

-$48.910m

-18.5%

1y CAGR

+2.9%

3y CAGR

+3.7%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.